Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03233347 · ClinicalTrials.gov registry record · Phase 2
Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma
A Phase 2 study of Classic Hodgkin Lymphoma and Ann Arbor Stage IIB Hodgkin Lymphoma, sponsored by Academic and Community Cancer Research United.
- Active
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
- 9
- Study locations
NCT03233347 is a Phase 2 study of Classic Hodgkin Lymphoma and Ann Arbor Stage IIB Hodgkin Lymphoma that is active but no longer recruiting, run by Academic and Community Cancer Research United. The registered enrollment target is 82 participants, below the 244-participant average among 9 other Classic Hodgkin Lymphoma trials with a reported enrollment target (66% lower). The trial reports 9 study locations across 9 states.
The verdict
NCT03233347, a Phase 2 study of Classic Hodgkin Lymphoma and Ann Arbor Stage IIB Hodgkin Lymphoma, is active but no longer recruiting, sponsored by Academic and Community Cancer Research United.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
- 9
- Study locations
Study Summary
This phase II trial evaluates how well AVD (doxorubicin, vinblastine, dacarbazine) in combination with brentuximab vedotin and nivolumab work in treating patients with stage I-II Hodgkin lymphoma. Drugs used in the chemotherapy, such as doxorubicin, vinblastine, dacarbazine, and brentuximab vedotin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, and/or by stopping them from spreading. Targeted agent, such as nivolumab, may interfere with the ability of cancer cells to grow and spread by enhancing the immune system. Giving doxorubicin, vinblastine, dacarbazine, brentuximab vedotin, and nivolumab may improve survival of patients with stage I-II Hodgkin lymphoma.
Conditions Studied
Interventions
- DRUG Doxorubicin
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Nivolumab
- DRUG Brentuximab Vedotin
- DRUG Dacarbazine
Study Locations (9)
California
- City of Hope Comprehensive Cancer Center - Duarte
Minnesota
- Mayo Clinic in Rochester - Rochester
Nebraska
- University of Nebraska Medical Center - Omaha
New Jersey
- Hackensack University Medical Center - Hackensack
North Carolina
- Carolinas Medical Center/Levine Cancer Institute - Charlotte
Pennsylvania
- University of Pennsylvania/Abramson Cancer Center - Philadelphia
Tennessee
- Vanderbilt University/Ingram Cancer Center - Nashville
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2017-10-13 |
| Est. Completion | 2026-07-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03233347
The ClinicalTrials.gov registry entry for NCT03233347 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 244-participant average among 9 other Classic Hodgkin Lymphoma trials with a reported enrollment target (66% lower). The listed sponsor is Academic and Community Cancer Research United, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Classic Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Doxorubicin is the first listed.
NCT03233347 reports 9 study locations spanning 9 distinct geographic areas - top geographies include California, Minnesota, Nebraska.
Frequently Asked Questions
What is clinical trial NCT03233347 about?
NCT03233347 is a clinical study titled "Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma". This phase II trial evaluates how well AVD (doxorubicin, vinblastine, dacarbazine) in combination with brentuximab vedotin and nivolumab work in treating patients with stage I-II Hodgkin lymphoma. Drugs used in the chemotherapy, such as doxorubicin, vinblastine, dacarbazine, and brentuximab vedotin,...
What is the current status of trial NCT03233347?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2017-10-13. Estimated completion is 2026-07-08.
What conditions does trial NCT03233347 study?
This clinical trial studies the following conditions: Classic Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma.
What interventions are being tested in trial NCT03233347?
The interventions under investigation include: Doxorubicin (DRUG), Laboratory Biomarker Analysis (OTHER), Nivolumab (BIOLOGICAL), Brentuximab Vedotin (DRUG), Dacarbazine (DRUG).
Who is sponsoring clinical trial NCT03233347?
This trial is sponsored by Academic and Community Cancer Research United, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03233347 being conducted?
This trial has 9 study locations across California, Minnesota, Nebraska, New Jersey, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Classic Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma
RECRUITING · Phase 2
-
MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma
RECRUITING · Phase 2
-
Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Classic Hodgkin Lymphoma
All registered trials for this condition
Ann Arbor Stage IIB Hodgkin Lymphoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.